The Effect of Tanshinone IIA upon the TGF-beta1/Smads signaling pathway in hypertrophic myocardium of hypertensive rats

Abstract

To investigate the molecular mechanism by which Tanshinone IIA (TSN IIA) prevents left ventricular hypertrophy (LVH), we examined the expression of AT1R, TGF-β1 and Smads gene in the hypertrophic myocardium of hypertensive rats with abdominal aorta constriction. LVH model was established by creating abdominal aorta constriction. Four weeks later, animals were randomly divided into 4 groups with 8 animals in each. One group was used as model control, the other three groups were treated with TSN IIA (20 mg/kg), TSN IIA (10 mg/kg) and valsartan (10 mg/kg), respectively. Another 8 SD rats were subjected to sham surgery and served as blank control. After 8-week treatment, the caudal artery pressure of the animals was measured. The tissues of left ventricle were taken for the measurement of the left ventricular mass index (LVMI) and pathological sectioning and HE-staining were used for determining the myocardial fiber dimension (MFD). The mRNA expression of AT1R, protein expression of TGF-beta1 and activity of Smad-2, 4, 7 were detected by RT-PCR and Western blotting, respectively. Our results showed that (1) the blood pressure of rats treated with TSN IIA, either at high or low dose, was significantly higher than those in the control and valsartan-treated group (P<0.01, P<0.05); (2) LVMI and MFD in TSN IIA and valsartan-treated rats were higher than those in the control group (P<0.05) but significantly lower than those in the model control (P<0.01); (3) the high doses of TSN IIA and valsartan significantly down-regulated the mRNA expression of AT1R and protein expression of TGF-beta1 and Smad-3 in the hypertrophic myocardium (P<0.01), and TGF-beta1 in valsartan-treated animals was more significantly lower than that in rats treated with TSN IIA; (4) the two doses of TSN IIA and valsartan significantly up-regulated the protein expression of Smad-7 in the hypertrophic myocardium (P<0.01), and Smad-7 in the animals treated with high-dose TSN IIA was significantly higher than that in rats treated with valsartan. It is concluded that inhibition of myocardial hypertrophy induced by TSN IIA independent of blood pressure. The underlying mechanism might be the down-regulated expression of AT1R mRNA and Smad-3, increased production of Smad-7, and blocking effect of TSN IIA on TGF beta1/Smads signal pathway in local myocardium.

Keywords

Tanshinone IIA / pressure overloading / myocardial hypertrophy / AT1R / TGF-beta1 / Smads

References

[1] CarreñoJ.E., ApablazaF., OcaranzaM. P., et al.. Cardiac hypertrophy: molecular and cellular events. Rev Esp Cardiol, 2006, 59(5): 473-486

[2] YasunariK., MaedaK., NakamuraM., et al.. Left ventricular hypertrophy and angiotensin II receptor blocking agents. Curr Med Chem Cardiovasc Hematol Agents, 2005, 3(1): 61-67

[3] KosugiR., ShioiT., Watanabe-MaedaK., et al.. Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. Circ, 2006, 70(4): 482-488

[4] Schultz JelJ., WittS.A., GlascockB.J., et al.. TGF-beta 1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest, 2002, 109(6): 787-795

[5] HaoJ., WangB., JonesS.C., et al.. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol, 2000, 279(6): 3020-3030

[6] LiY.S., WangZ.H., YanL., et al.. Effect of tashinone on nitric oxide synthase in hypertrophic cadiocyte of rats suffered abdominal aorta constriction. Zhongguo Zhong Yao Za Zhi (Chinese), 2008, 33(12): 1446-1450

[7] WangZ.H., LiangQ.S., ZhengZ.. The effect of tanshinone on L-type calcium current in hypertrophic myocardium. Chin J Hypertension (Chinese), 2006, 14(6): 450-454

[8] ZhanC.Y., TaoX.L., HanS.J., et al.. Effects of tanshinone II A on the cardiac content of aldosterone and the expression of CYP11B1 and CYP11B2 mRNA related to aldosterone synthesis in spontaneously hypertensive rats. Chin Pharm J (Chinese), 2005, 40(1): 31-33

[9] RoseM., BalakumarP., SinghM., et al.. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology, 2007, 80(2–3): 177-184

[10] ZhouD., LiangQ., HeX., et al.. Changes of c-fos and c-jun mRNA expression in angiotensin II-induced cardiomyocyte hypertrophy and effects of sodium tanshinone IIA sulfonate. J Huazhong Univ Sci Technol [Med Sci], 2008, 28(5): 531-534

[11] Ruiz-OrtegaM., Rodríguez-VitaJ., Sanchez-LopezE., et al.. TGF-beta signaling in vascular fibrosis. Cardiovasc Res, 2007, 74(2): 196-206

[12] ChenL.L., YinH., HuangJ.. Inhibition of TGF-beta1 signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through angiogenesis and reduction of apoptosis. Cardiovasc Pathol, 2007, 16(4): 221-230

[13] RosenkranzS., FleschM., BohmM., et al.. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta (1). Am J Physiol Heart Circ Physiol, 2002, 283(3): 1253-1262

[14] ZhangR.Y., WangL.F., ZhangL., et al.. Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats. Chin Med J (Engl), 2006, 119(8): 649-655

[15] Chuva de Sousa LopesS.M., FeijenA., KorvingJ., et al.. Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. Dev Dyn, 2004, 231(3): 542-550

[16] BrandT., SchneiderM.D.. The TGF-β superfamily in myocardium:ligands, receptors, transduction, and function. J Mol Cell, 1995, 27(1): 5-18

[17] ShiY., MassagueJ.. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell, 2003, 113(6): 685-700

[18] Carl-HenrikH., KoheiM., PeterT., et al.. TGF-β1 signalling from cell membrance to nucleus through SMAD proteins. Nature, 1997, 390(4): 465-471

[19] XiaoH., ZhangY.Y.. Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol, 2008, 35(3): 335-341

[20] DongC., LiZ., AlvarezR., et al.. Microtubule binding to SMADs may regulate TGF-beta activity. Mol Cell, 2000, 5(1): 27-34

[21] PokharelS., van GeelP.P., SharmaU.C., et al.. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation, 2004, 110(19): 3129-3135

[22] WangB., HaoJ., JonesS.C., et al.. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol, 2002, 282(5): H1685-H1696

[23] HuangJ., QING.H., HUC.X., et al.. Effects of transforming growth factor-beta1 and signal protein Smad3 on rat cardiomyocyte hypertrophy. Chin Med J (Engl), 2004, 117(10): 1471-1475

[24] ZhaiY., GaoX., WuQ., et al.. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol, 2008, 587(1–3): 196-203

[25] ItohS., ten DijkeP.. Negative regulation of TGF-β receptor/ Smad signal transduction. Curr Opin Cell Biol, 2007, 19(2): 176-184

[26] SongL., YanW., ChenX., et al.. Myocardial smad4 is essential for cardiogenesis in mouse embryos. Circ Res, 2007, 101(3): 277-285

[27] TangJ., ZhanC., ZhouJ.. Effects of tanshinone IIA on transforming growth factor beta1-Smads signal pathway in renal interstitial fibroblasts of rats. J Huazhong Univ Sci Technolog [Med Sci], 2008, 28(5): 539-542

[28] LiY.S., WangZ.H., WangJ., et al.. The effect and molecular mechanism of Tashinon IIA on the hypertrophic cadiocyte due to abdominal aorta stenosis in rats. Chin Pharm J (Chinese), 2008, 43(17): 1313-1317